Chinese R&D Center Planned By Novartis Oncology In Shanghai
This article was originally published in PharmAsia News
Executive Summary
China is the focus of a new effort by Novartis Oncology to expand research-and-development work abroad
You may also be interested in...
Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.
Need a specific report? 1000+ reports available
Buy Reports